Regular exercise, plasminogen activator inhibitor-1 (PAI-I) activity and the 4G/5G promoter polymorphism in the PAI-1 gene

被引:0
|
作者
Väisänen, SB
Humphries, SE
Luong, LA
Penttilä, I
Bouchard, C
Rauramaa, R
机构
[1] Univ Kuopio, Kuopio Res Inst Exercise Med, FIN-70100 Kuopio, Finland
[2] Univ Kuopio, Dept Physiol, FIN-70100 Kuopio, Finland
[3] UCLMS, Rayne Inst, Dept Med, Ctr Cardiovasc Genet, London, England
[4] Kuopio Univ Hosp, Dept Clin Chem, SF-70210 Kuopio, Finland
[5] Univ Laval, Phys Act Sci Lab, St Foy, PQ G1K 7P4, Canada
[6] Kuopio Univ Hosp, Dept Clin Physiol & Nucl Med, SF-70210 Kuopio, Finland
关键词
plasminogen activator inhibitor-1; DNA polymorphism; exercise training; randomised clinical trial; population based study;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this controlled randomised clinical trial was to investigate the effects of regular low to moderate intensity physical activity on plasminogen activator inhibitor-1 (PAI-1) activity during three years while taking into account the 4G/5G polymorphism in the promoter of the PAI-1 gene. Male subjects (age 52-62 years, n = 132) were randomised into an exercise or a (non-intervention) reference group. Aerobic threshold increased by 8.8% (p = 0.025) in the exercise group, and decreased by 1.1% in the non-intervention group, while PAI-1 activity did not change significantly in either study group. However! homo zygotes for the 4G allele in the exercise group showed a 36% reduction in PAI-1 (p = 0.025). In conclusion, although regular moderate physical activity did not decrease PAI-1 activity in the whole group, regular exercise ma) be effective for controlling elevated PAI-1 level in subjects homozygous for the 4G allele.
引用
收藏
页码:1117 / 1120
页数:4
相关论文
共 50 条
  • [1] Role of 4G/5G promoter polymorphism of Plasminogen Activator Inhibitor-1 (PAI-1) gene in outcome of sepsis
    Peres Wingeyer, Silvia
    de Larranaga, Gabriela
    Fontana, Laura
    Cunto, Eleonora
    Nogueras, Cristina
    San Juan, Jorge
    THROMBOSIS RESEARCH, 2010, 125 (04) : 367 - 369
  • [2] Association of plasminogen activator inhibitor-1 (PAI-1) gene promoter 4G/5G polymorphism with plasma PAI-1 level in patients with hypertension
    Jeng, JR
    Harn, HJ
    Shieh, SM
    ATHEROSCLEROSIS, 1999, 144 : 64 - 64
  • [3] Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer
    Blasiak, J
    Smolarz, B
    ACTA BIOCHIMICA POLONICA, 2000, 47 (01) : 191 - 199
  • [4] The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: Relationship to plasma PAI-1 level in venous thromboembolism
    Stegnar, M
    Uhrin, P
    Peternel, P
    Mavri, A
    Salobir-Pajnic, B
    Stare, J
    Binder, BR
    THROMBOSIS AND HAEMOSTASIS, 1998, 79 (05) : 975 - 979
  • [5] Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and endometriosis. Influence of PAI-1 polymorphism on PAI-1 antigen and mRNA expression
    Ramon, Luis A.
    Gilabert-Estelles, Juan
    Cosin, Raul
    Gilabert, Juan
    Espana, Francisco
    Castello, Remedios
    Chirivella, Melitina
    Romeu, Alberto
    Estelles, Amparo
    THROMBOSIS RESEARCH, 2008, 122 (06) : 854 - 860
  • [6] Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease
    Catto, AJ
    Carter, AM
    Stickland, M
    Bamford, JM
    Davies, JA
    Grant, PJ
    THROMBOSIS AND HAEMOSTASIS, 1997, 77 (04) : 730 - 734
  • [7] Plasminogen activator inhibitor-1 (PAI-1) content in platelets from healthy individuals genotyped for the 4G/5G polymorphism in the PAI-1 gene
    Nordenhem, A
    Wiman, B
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1997, 57 (05): : 453 - 461
  • [8] Acute-phase levels of plasminogen activator inhibitor-1 (PAI-1) and the 4G/5G PAW promoter polymorphism
    Andreotti, F
    Burzotta, F
    Di Castelnuovo, A
    Schiavello, R
    Donati, MB
    Maseri, A
    Possati, GF
    Iacoviello, L
    EUROPEAN HEART JOURNAL, 2002, 23 : 672 - 672
  • [9] Role of 4G/5G plasminogen activator inhibitor-1 (PAI-1) gene polymorphism and the PAI-1 plasma levels in the outcome of patients with severe sepsis
    L Lorente
    M Martín
    L Labarta
    C Díaz
    J Solé-Violán
    J Blanquer
    J Borreguero
    Y Barrios
    Critical Care, 13 (Suppl 1):
  • [10] The plasminogen activator inhibitor (PAI-I) 4G/5G promoter polymorphism and PAI-I levels in ischemic stroke -: A case-control study
    van Goor, ML
    García, EG
    Leebeek, F
    Brouwers, GJ
    Koudstaal, P
    Dippel, D
    THROMBOSIS AND HAEMOSTASIS, 2005, 93 (01) : 92 - 96